A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea
Status:
Terminated
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This Phase I double blind, randomized clinical study to evaluate the safety of human milk
oligosaccharides (HMO) is designed to assess the safety and dosage ranging of PBCLN-003 in
adults with Clostridium difficile-associated diarrhea (CDAD). Within 3 dose cohort, subjects
will be randomized in a 3:1 ratio to receive PBCLN-003 or placebo.